The carboxyl terminus of VEGF-A is a potential target for anti-angiogenic therapy

Anti-VEGF-A therapy has become a mainstay of treatment for ocular neovascularisation and in cancer; however, their effectiveness is not universal, in some cases only benefiting a minority of patients. Anti-VEGF-A therapies bind and block both pro-angiogenic VEGF-A(xxx) and the partial agonist VEGF-A...

Descripción completa

Detalles Bibliográficos
Autores principales: Carter, James G., Gammons, Melissa V. R., Damodaran, Gopinath, Churchill, Amanda J., Harper, Steven J., Bates, David O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2014
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4280485/
https://www.ncbi.nlm.nih.gov/pubmed/25274272
http://dx.doi.org/10.1007/s10456-014-9444-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4280485/
https://www.ncbi.nlm.nih.gov/pubmed/25274272
http://dx.doi.org/10.1007/s10456-014-9444-3

Ejemplares similares